




ELiBio analysis Report


Examen Reference : KM2025AE Examen Date : 02/17/2025
Patient Name : John Doe Analysis Date : 02/17/2025
Patient Sex : Male Referrer Name : Dr House

PDFF (%): 10.5 ± 4.7 Susceptibility (ppm): -0.001 ± 0.107 R2* (s^-1): 29.3 ± 6 Iron Content (mg/g): 0.6 ± 0.2









Liver Iron Content and corresponding clinical relevance.

< 1.8 mg/g dry weight	Normal iron level: no iron overload, typical healthy individual without iron storage disorders.
1.8 - 3.2 mg/g dry weight	Mild iron level: no iron overload, heterozygous hereditary hemochromatosis, early transfusional loading, or metabolic syndrome-related iron accumulation. Requires monitoring
3.2 - 7 mg/g dry weight	Moderate iron overload: Associated with hereditary hemochromatosis or repeated transfusions, Increased risk of liver fibrosis and potential organ damage.
7 - 15 mg/g dry weight	Severe iron overload: High risk of liver cirrhosis, cardiomyopathy, and endocrine dysfunction. Common in polytransfusion states.
> 15 mg/g dry weight	Extreme iron overload: Very high risk of life-threatening complications, (hepatocellular carcinoma, cardiac failure) and severe organ dysfunction. Requires urgent management.

Proton Density Fat Fraction and corresponding clinical relevance.

< 6%	No significant hepatic steatosis.
6 - 16%	Mild Hepatic Steatosis: Suggests early-stage NAFLD. Typically asymptomatic but may require monitoring
16 - 21%	Moderate Hepatic Steatosis: Associated with more pronounced NAFLD. May show early metabolic changes and requires intervention.
> 21%	Severe Hepatic Steatosis: Indicates advanced fat accumulation. Higher risk of progression to NASH and liver fibrosis, cirrhosis, and complications such as hepatocellular carcinoma.